-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

Benzinga·08/07/2026 15:21:37
Listen to the news
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.